title: [Renal failure during treatment with Ambisome].
abstract: BACKGROUND
  Although renal function is generally unaffected by liposome formulations of amphotericin B-deoxycholate, there is nevertheless a risk.
  
  
  METHODS
  Two patients immunodepressed patients treated for candidosis involving the mouth and esophagus unresponsive to local care and flucanazol developed renal failure when given the liposome formulation of amphotericin B-deoxycholate (AmBisome). In one with normal renal function prior to treatment, moderate impairment was observed after initiating AmBisome. In the second patient, impaired renal function worsened after initiating treatment with amphotericin B-deoxycholate then progressed to very severe renal failure after switching to AmBisome.
  
  
  CONCLUSIONS
  The indication for AmBisome (amphotericin B-deoxycholate treatment in patients with active renal impairment) must not overshadow the risk of worsening renal function under treatment.
authors.affiliation: Clinique des Maladies infectieuses et Réanimation médicale, CHRU Pontchaillou, Rennes. Cedric.Arvieux@univ-rennes1.fr
authors.forename: C
authors.initials: C
authors.lastname: Arvieux
authors.forename: V
authors.initials: V
authors.lastname: Noyon
authors.forename: C
authors.initials: C
authors.lastname: Michelet
authors.forename: F
authors.initials: F
authors.lastname: Cartier
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects*; D000935:Antifungal Agents / Q000009:adverse effects*; D002177:Candidiasis / Q000188:drug therapy; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D051437:Renal Insufficiency / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B